What is Century Therapeutics, Inc. (IPSC)?

Century Therapeutics, Inc. (IPSC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of IPSC?

The current price of IPSC is $1.50. Prices are updated in real time on Stocks360.

What is IPSC's price-to-earnings (PE) ratio?

IPSC's trailing twelve-month PE ratio is -1.44, based on current price and earnings per share data available on Stocks360.

What is IPSC's market capitalization?

IPSC's market capitalization is $271,612,982.00, placing it in the small-cap tier.

Century Therapeutics, Inc. (IPSC)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.50

Market Cap

$271.61M

PE (TTM)

-1.44

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.67

Day Range

$1.43 – $1.51

52-wk Range

$0.44 – $3.04

Avg Volume

N/A

Volume

839.75K

Century Therapeutics, Inc. (IPSC) is a publicly traded company in the Healthcare sector. Latest price: $1.50. Market cap $271.61M. Trailing PE -1.44. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $0.58 2026-10-28 · $1.50 (+160.10%)

Earnings

Most Recent

Aug 12, 2026

EPS $-0.17 vs est. $-0.11

Missed by $0.06

Next Earnings

Nov 12, 2026

EPS estimate $-0.12

Proprietary Signals

Signal snapshot temporarily unavailable.

About Century Therapeutics, Inc.

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.44×
P/S (TTM)	0.00×
P/B	1.33×
PEG	0.00×
P/FCF (TTM)	-3.07×
EV / EBITDA	-2.77×
EV / Sales	0.00×
Earnings Yield	-35.57%
Free Cash Flow Yield	-32.59%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$256.60M
Net Income (TTM)	-$96.61M
Free Cash Flow (TTM)	-$88.53M
Net Debt	-$15.02M
Working Capital	$109.70M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-52.76%
Return on Invested Capital	-43.66%